{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T19:39:10Z","timestamp":1794512350534,"version":"4.9.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,2,10]],"date-time":"2012-02-10T00:00:00Z","timestamp":1328832000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/3.0\/"},{"start":{"date-parts":[[2012,2,10]],"date-time":"2012-02-10T00:00:00Z","timestamp":1328832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/3.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/srep00259","type":"journal-article","created":{"date-parts":[[2012,2,10]],"date-time":"2012-02-10T10:52:47Z","timestamp":1328871167000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["An orally available, small-molecule interferon inhibits viral replication"],"prefix":"10.1038","volume":"2","author":[{"given":"Hideyuki","family":"Konishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Ohmori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ohmori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motooki","family":"Ashihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsunori","family":"Ohta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuko","family":"Hada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asao","family":"Katsume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michinori","family":"Kohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumi","family":"Morikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuo","family":"Tsukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuo","family":"Shimma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham R.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Alazawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikio","family":"Arisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Sudoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,2,10]]},"reference":[{"key":"BFsrep00259_CR1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1478-3231.2008.01934.x","volume":"29","author":"D Lavanchy","year":"2009","unstructured":"Lavanchy, D. The global burden of hepatitis. Liver Int. 29, 74\u201381 (2009).","journal-title":"Liver Int."},{"key":"BFsrep00259_CR2","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","volume":"49","author":"MG Ghany","year":"2009","unstructured":"Ghany, M. G., Strader, D. B., Thomas, D. L. & Seeff, L. B. Diagnosis, management and treatment of hepatitis C: an update. Hepatology. 49, 1335\u201374 (2009).","journal-title":"Hepatology."},{"key":"BFsrep00259_CR3","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/ncpgasthep1274","volume":"5","author":"S Zeuzem","year":"2008","unstructured":"Zeuzem, S. Interferon-based therapy for chronic hepatitis C: current and future perspectives. Nat Clin Pract Gastroenterol Hepatol. 5, 610\u2013622 (2008).","journal-title":"Nat Clin Pract Gastroenterol Hepatol."},{"key":"BFsrep00259_CR4","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","volume":"461","author":"D Ge","year":"2009","unstructured":"Ge, D. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 461, 399\u2013401 (2009).","journal-title":"Nature."},{"key":"BFsrep00259_CR5","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/ng.447","volume":"41","author":"V Suppiah","year":"2009","unstructured":"Suppiah, V. et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 41, 1100\u20134 (2009).","journal-title":"Nat Genet."},{"key":"BFsrep00259_CR6","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/ng.449","volume":"41","author":"Y Tanaka","year":"2009","unstructured":"Tanaka, Y. et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. . Nat Genet.41, 1105\u20139 (2009).","journal-title":"Nat Genet"},{"key":"BFsrep00259_CR7","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nature08463","volume":"461","author":"DL Thomas","year":"2009","unstructured":"Thomas, D. L. et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 461, 798\u2013801 (2009).","journal-title":"Nature."},{"key":"BFsrep00259_CR8","doi-asserted-by":"crossref","first-page":"734","DOI":"10.20452\/pamw.542","volume":"118","author":"J Czepiel","year":"2008","unstructured":"Czepiel, J., Czepiel, J., Biesiada, G. & Mach, T. Viral hepatitis C. .Pol Arch Med Wewn. 118, 734\u2013740 (2008).","journal-title":"Pol Arch Med Wewn."},{"key":"BFsrep00259_CR9","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S1473-3099(09)70020-9","volume":"9","author":"DP Webster","year":"2009","unstructured":"Webster, D. P., Klenerman, P., Collier, J. & Jeffery, K. J. Development of novel treatments for hepatitis C. .Lancet Infect Dis. 9, 108\u2013117 (2009).","journal-title":"Lancet Infect Dis."},{"key":"BFsrep00259_CR10","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","volume":"364","author":"IM Jacobson","year":"2011","unstructured":"Jacobson, I. M. et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 364, 2405\u201316 (2011).","journal-title":"N Engl J Med."},{"key":"BFsrep00259_CR11","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","volume":"364","author":"F Poordad","year":"2011","unstructured":"Poordad, F. et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 364, 1195\u2013206 (2011).","journal-title":"N Engl J Med."},{"key":"BFsrep00259_CR12","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.coph.2008.09.007","volume":"8","author":"AD Kwong","year":"2008","unstructured":"Kwong, A. D., McNair, L., Jacobson, I. & George, S. Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors. Curr Opin Pharmacol. 8, 522\u2013531 (2008).","journal-title":"Curr Opin Pharmacol."},{"key":"BFsrep00259_CR13","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev.biochem.67.1.227","volume":"67","author":"GR Stark","year":"1998","unstructured":"Stark, G. R. et al. How cells respond to interferons. Annu Rev Biochem. 67, 227\u2013264 (1998).","journal-title":"Annu Rev Biochem."},{"key":"BFsrep00259_CR14","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1189\/jlb.69.6.912","volume":"69","author":"MJ de Veer","year":"2001","unstructured":"de Veer, M. J. et al. Functional classification of interferon-stimulated genes identified using microarrays. J Leukoc Biol. 69, 912\u201320 (2001).","journal-title":"J Leukoc Biol."},{"key":"BFsrep00259_CR15","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1146\/annurev.bi.56.070187.003455","volume":"56","author":"S Pestka","year":"1987","unstructured":"Pestka, S., Langer, J. A., Zoon, K. C. & Samuel, C. E. Interferons and their actions. Annu Rev Biochem. 56, 727\u2013777 (1987).","journal-title":"Annu Rev Biochem."},{"key":"BFsrep00259_CR16","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0092-8674(90)90738-Z","volume":"60","author":"G Uze","year":"1990","unstructured":"Uze, G., Lutfalla, G. & Gresser, I. Genetic transfer of a functional human interferon alpha receptor into mouse cells: cloning and expression of its cDNA. Cell. 60, 225\u2013234 (1990).","journal-title":"Cell."},{"key":"BFsrep00259_CR17","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/0092-8674(94)90154-6","volume":"77","author":"D Novick","year":"1994","unstructured":"Novick, D., Cohen, B. & Rubinstein, M. The human interferon alpha\/beta receptor: characterization and molecular cloning. Cell. 77, 391\u2013400 (1994).","journal-title":"Cell."},{"key":"BFsrep00259_CR18","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1126\/science.285.5424.110","volume":"285","author":"V Lohmann","year":"1999","unstructured":"Lohmann, V. et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science. 285, 110\u2013113 (1999).","journal-title":"Science."},{"key":"BFsrep00259_CR19","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nchembio742","volume":"1","author":"H Sakamoto","year":"2005","unstructured":"Sakamoto, H. et al. Host sphingolipid biosynthesis as a target for hepatitis C virus therapy. Nat Chem Biol. 1, 333\u2013337 (2005).","journal-title":"Nat Chem Biol."},{"key":"BFsrep00259_CR20","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/nm1268","volume":"11","author":"T Wakita","year":"2005","unstructured":"Wakita, T. et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med. 11, 791\u2013796 (2005).","journal-title":"Nat Med."},{"key":"BFsrep00259_CR21","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/hep.21209","volume":"43","author":"NM Kneteman","year":"2006","unstructured":"Kneteman, N. M. et al. Anti-HCV therapies in chimeric scid-Alb\/uPA mice parallel outcomes in human clinical application. Hepatology. 43, 1346\u20131353 (2006).","journal-title":"Hepatology."},{"key":"BFsrep00259_CR22","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1478-3231.2005.01082.x","volume":"25","author":"S Dash","year":"2005","unstructured":"Dash, S. et al. Interferons alpha, beta, gamma each inhibit hepatitis C virus replication at the level of internal ribosome entry site-mediated translation. Liver Int. 25, 580\u2013594 (2005).","journal-title":"Liver Int."},{"key":"BFsrep00259_CR23","doi-asserted-by":"crossref","first-page":"15623","DOI":"10.1073\/pnas.95.26.15623","volume":"95","author":"SD Der","year":"1998","unstructured":"Der, S. D., Zhou, A., Williams, B. R. & Silverman, R. H. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci U S A. 95, 15623\u201315628 (1998).","journal-title":"Proc Natl Acad Sci U S A."},{"key":"BFsrep00259_CR24","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/ni758","volume":"3","author":"H Hemmi","year":"2002","unstructured":"Hemmi, H. et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol. 3, 196\u2013200 (2002).","journal-title":"Nat Immunol."},{"key":"BFsrep00259_CR25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1196\/annals.1443.020","volume":"1143","author":"T Kawai","year":"2008","unstructured":"Kawai, T. & Akira, S. Toll-like receptor and RIG-I-like receptor signaling. Ann N Y Acad Sci. 1143, 1\u201320 (2008).","journal-title":"Ann N Y Acad Sci."},{"key":"BFsrep00259_CR26","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1126\/science.1087262","volume":"301","author":"M Yamamoto","year":"2003","unstructured":"Yamamoto, M. et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science. 301, 640\u20133 (2003).","journal-title":"Science."},{"key":"BFsrep00259_CR27","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.4049\/jimmunol.162.7.3749","volume":"162","author":"K Hoshino","year":"1999","unstructured":"Hoshino, K. et al. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol. 162, 3749\u201352 (1999).","journal-title":"J Immunol."},{"key":"BFsrep00259_CR28","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/35047123","volume":"408","author":"H Hemmi","year":"2000","unstructured":"Hemmi, H. et al. A Toll-like receptor recognizes bacterial DNA. Nature. 408, 740\u20135 (2000).","journal-title":"Nature."},{"key":"BFsrep00259_CR29","first-page":"2279","volume":"6","author":"JD Mosca","year":"1986","unstructured":"Mosca, J. D. & Pitha, P. M. Transcriptional and posttranscriptional regulation of exogenous human beta interferon gene in simian cells defective in interferon synthesis. Mol Cell Biol. 6, 2279\u201383 (1986).","journal-title":"Mol Cell Biol."},{"key":"BFsrep00259_CR30","doi-asserted-by":"crossref","first-page":"5259","DOI":"10.1073\/pnas.85.14.5259","volume":"85","author":"MO Diaz","year":"1988","unstructured":"Diaz, M. O. et al. Homozygous deletion of the alpha- and beta 1-interferon genes in human leukemia and derived cell lines. Proc Natl Acad Sci U S A. 85, 5259\u201363 (1988).","journal-title":"Proc Natl Acad Sci U S A."},{"key":"BFsrep00259_CR31","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1349-7006.2008.01051.x","volume":"100","author":"HM Chen","year":"2009","unstructured":"Chen, H. M. et al. Critical role for constitutive type I interferon signaling in the prevention of cellular transformation. Cancer Sci. 100, 449\u201356 (2009).","journal-title":"Cancer Sci."},{"key":"BFsrep00259_CR32","doi-asserted-by":"crossref","first-page":"5100","DOI":"10.1002\/j.1460-2075.1995.tb00192.x","volume":"14","author":"G Lutfalla","year":"1995","unstructured":"Lutfalla, G. et al. Mutant U5A cells are complemented by an interferon-alpha beta receptor subunit generated by alternative processing of a new member of a cytokine receptor gene cluster. EMBO J. 14, 5100\u20135108 (1995).","journal-title":"EMBO J."},{"key":"BFsrep00259_CR33","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0092-8674(92)90105-L","volume":"70","author":"L Velazquez","year":"1992","unstructured":"Velazquez, L. Fellous, M. Stark, G. R. & Pellegrini, S. A protein tyrosine kinase in the interferon alpha\/beta signaling pathway. Cell. 70, 313\u201322 (1992).","journal-title":"Cell."},{"key":"BFsrep00259_CR34","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1006\/jmbi.1998.2026","volume":"282","author":"M Lewerenz","year":"1998","unstructured":"Lewerenz, M. Mogensen, K. E. & Uz\u00e9, G. Shared receptor components but distinct complexes for alpha and beta interferons. J Mol Biol. 282, 585\u201399 (1998).","journal-title":"J Mol Biol."},{"key":"BFsrep00259_CR35","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/0092-8674(94)90357-3","volume":"76","author":"K Shuai","year":"1994","unstructured":"Shuai, K. et al. Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions. Cell. 76, 821\u2013828 (1994).","journal-title":"Cell."},{"key":"BFsrep00259_CR36","doi-asserted-by":"crossref","first-page":"7034","DOI":"10.1073\/pnas.0707882105","volume":"105","author":"M Sarasin-Filipowicz","year":"2008","unstructured":"Sarasin-Filipowicz, M. et al. Interferon signaling and treatment outcome in chronic hepatitis C. .Proc Natl Acad Sci U S A. 105, 7034\u20139 (2008).","journal-title":"Proc Natl Acad Sci U S A."},{"key":"BFsrep00259_CR37","doi-asserted-by":"crossref","first-page":"e11031","DOI":"10.1371\/journal.pone.0011031","volume":"5","author":"A Farnsworth","year":"2010","unstructured":"Farnsworth, A. et al. Acetaminophen modulates the transcriptional response to recombinant interferon-beta. PloS One. 5, e11031 (2010).","journal-title":"PloS One."},{"key":"BFsrep00259_CR38","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/90968","volume":"7","author":"DF Mercer","year":"2001","unstructured":"Mercer, D. F. et al. Hepatitis C virus replication in mice with chimeric human livers. Nat Med. 7, 927\u201333 (2001).","journal-title":"Nat Med."},{"key":"BFsrep00259_CR39","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1128\/MCB.15.3.1312","volume":"15","author":"S Leung","year":"1995","unstructured":"Leung, S. et al. Role of STAT2 in the alpha interferon signaling pathway. Mol Cell Biol. 15, 1312\u20131317 (1995).","journal-title":"Mol Cell Biol."},{"key":"BFsrep00259_CR40","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1074\/jbc.271.10.5790","volume":"271","author":"X Li","year":"1996","unstructured":"Li, X. et al. Formation of STAT1-STAT2 heterodimers and their role in the activation of IRF-1 gene transcription by interferon-alpha. J Biol Chem. 271, 5790\u20134 (1996).","journal-title":"J Biol Chem."},{"key":"BFsrep00259_CR41","doi-asserted-by":"crossref","first-page":"12408","DOI":"10.1074\/jbc.271.21.12408","volume":"271","author":"JJ Ghislain","year":"1996","unstructured":"Ghislain, J. J. & Fish, E. N. Application of genomic DNA affinity chromatography identifies multiple interferon-alpha-regulated Stat2 complexes. J Biol Chem. 271, 12408\u201313 (1996).","journal-title":"J Biol Chem."},{"key":"BFsrep00259_CR42","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.4049\/jimmunol.163.7.3834","volume":"163","author":"S Gupta","year":"1999","unstructured":"Gupta, S. Jiang, M. & Pernis, A. B. IFN-alpha activates Stat6 and leads to the formation of Stat2:Stat6 complexes in B cells. J Immunol. 163, 3834\u201341 (1999).","journal-title":"J Immunol."},{"key":"BFsrep00259_CR43","doi-asserted-by":"crossref","first-page":"e1001297","DOI":"10.1371\/journal.ppat.1001297","volume":"7","author":"ST Perry","year":"2011","unstructured":"Perry, S. T., Buck, M. D., Lada, S. M., Schindler, C. & Shresta, S. STAT2 Mediates Innate Immunity to Dengue Virus in the Absence of STAT1 via the Type I Interferon Receptor. PloS Pathogens. 7, e1001297 (2011).","journal-title":"PloS Pathogens."},{"key":"BFsrep00259_CR44","doi-asserted-by":"crossref","first-page":"34838","DOI":"10.1074\/jbc.274.49.34838","volume":"274","author":"E Pattyn","year":"1999","unstructured":"Pattyn, E. et al. Dimerization of the interferon type I receptor IFNaR2-2 is sufficient for induction of interferon effector genes but not for full antiviral activity. J Biol Chem. 274, 34838\u201345 (1999).","journal-title":"J Biol Chem."},{"key":"BFsrep00259_CR45","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1089\/107999003322558791","volume":"23","author":"D Platis","year":"2003","unstructured":"Platis, D. & Foster, G. R. Activity of hybrid type I interferons in cells lacking Tyk2: a common region of IFN-alpha 8 induces a response, but IFN-alpha2\/8 hybrids can behave like IFN-beta. J Interferon Cytokine Res. 23, 655\u201366 (2003).","journal-title":"J Interferon Cytokine Res."},{"key":"BFsrep00259_CR46","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMoa0806104","volume":"360","author":"JG McHutchison","year":"2009","unstructured":"McHutchison, J. G. et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 360, 1827\u201338 (2009).","journal-title":"N Engl J Med."},{"key":"BFsrep00259_CR47","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa0807650","volume":"360","author":"C H\u00e9zode","year":"2009","unstructured":"H\u00e9zode, C. et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 360, 1839\u201350 (2009).","journal-title":"N Engl J Med."},{"key":"BFsrep00259_CR48","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/hep.22717","volume":"49","author":"NM Kneteman","year":"2009","unstructured":"Kneteman, N. M. et al. HCV796: A selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers and in humans infected with hepatitis C virus. Hepatology. 49, 745\u201352 (2009).","journal-title":"Hepatology."},{"key":"BFsrep00259_CR49","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1073\/pnas.91.4.1198","volume":"91","author":"JU Gutterman","year":"1994","unstructured":"Gutterman, J. U. Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci U S A. 91, 1198\u20131205 (1994).","journal-title":"Proc Natl Acad Sci U S A."},{"key":"BFsrep00259_CR50","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S0016-5085(99)70185-X","volume":"116","author":"T Takeuchi","year":"1999","unstructured":"Takeuchi, T. et al. Real-time detection system for quantification of hepatitis C virus genome. Gastroenterology. 116, 636\u2013642 (1999).","journal-title":"Gastroenterology."},{"key":"BFsrep00259_CR51","unstructured":"Yabuta, N. et al. Method for screening ligand having biological activity. PCT Int. Appl. WO0206838 (2002)."},{"key":"BFsrep00259_CR52","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/hep.21587","volume":"45","author":"K Inoue","year":"2007","unstructured":"Inoue, K. et al. Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo. Hepatology. 45, 921\u20138 (2007).","journal-title":"Hepatology."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep00259","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep00259.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep00259.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T09:32:35Z","timestamp":1742463155000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep00259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,10]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2012,12,21]]}},"alternative-id":["BFsrep00259"],"URL":"https:\/\/doi.org\/10.1038\/srep00259","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,10]]},"assertion":[{"value":"7 November 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"259"}}